140 related articles for article (PubMed ID: 21292776)
21. H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets.
Liu HD; Zhang AJ; Xu JJ; Chen Y; Zhu YC
J Hematol Oncol; 2016 Feb; 9():13. PubMed ID: 26912146
[TBL] [Abstract][Full Text] [Related]
22. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis.
Nagata Y; Shozaki Y; Nagahisa H; Nagasawa T; Abe T; Todokoro K
Thromb Haemost; 1997 May; 77(5):808-14. PubMed ID: 9184382
[TBL] [Abstract][Full Text] [Related]
23. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
Pecci A; Malara A; Badalucco S; Bozzi V; Torti M; Balduini CL; Balduini A
Thromb Haemost; 2009 Jul; 102(1):90-6. PubMed ID: 19572073
[TBL] [Abstract][Full Text] [Related]
24. Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin.
Giver CR; Jaye DL; Waller EK; Lonial S
Exp Hematol; 2012 Feb; 40(2):95-6. PubMed ID: 22101254
[No Abstract] [Full Text] [Related]
25. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
Eckly A; Strassel C; Freund M; Cazenave JP; Lanza F; Gachet C; Léon C
Blood; 2009 Apr; 113(14):3182-9. PubMed ID: 18984861
[TBL] [Abstract][Full Text] [Related]
26. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
[TBL] [Abstract][Full Text] [Related]
27. Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3.
Larson MK; Watson SP
Blood; 2006 Sep; 108(5):1509-14. PubMed ID: 16670270
[TBL] [Abstract][Full Text] [Related]
28. Actin inhibition increases megakaryocyte proplatelet formation through an apoptosis-dependent mechanism.
Avanzi MP; Izak M; Oluwadara OE; Mitchell WB
PLoS One; 2015; 10(4):e0125057. PubMed ID: 25875470
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Zhou L; He X; Gao B; Xiong S
J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
31. Induction of platelet formation from megakaryocytoid cells by nitric oxide.
Battinelli E; Willoughby SR; Foxall T; Valeri CR; Loscalzo J
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14458-63. PubMed ID: 11734646
[TBL] [Abstract][Full Text] [Related]
32. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
33. Regulation of platelet lifespan by apoptosis.
Lebois M; Josefsson EC
Platelets; 2016 Sep; 27(6):497-504. PubMed ID: 27100842
[TBL] [Abstract][Full Text] [Related]
34. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.
Majka M; Ratajczak J; Villaire G; Kubiczek K; Marquez LA; Janowska-Wieczorek A; Ratajczak MZ
Exp Hematol; 2002 Jul; 30(7):751-60. PubMed ID: 12135673
[TBL] [Abstract][Full Text] [Related]
35. Modulation of Donor-Specific Antibody Production After Organ Transplantation by Valproic Acid: A Histone Deacetylase Inhibitor.
Ye J; Li J; Zhou M; Xia R; Liu R; Yu L
Transplantation; 2016 Nov; 100(11):2342-2351. PubMed ID: 27140514
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Díaz-Núñez M; Díez-Torre A; De Wever O; Andrade R; Arluzea J; Silió M; Aréchaga J
BMC Cancer; 2016 Aug; 16(1):667. PubMed ID: 27549189
[TBL] [Abstract][Full Text] [Related]
37. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR
J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761
[TBL] [Abstract][Full Text] [Related]
38. Podoplanin-positive periarteriolar stromal cells promote megakaryocyte growth and proplatelet formation in mice by CLEC-2.
Tamura S; Suzuki-Inoue K; Tsukiji N; Shirai T; Sasaki T; Osada M; Satoh K; Ozaki Y
Blood; 2016 Mar; 127(13):1701-10. PubMed ID: 26796360
[TBL] [Abstract][Full Text] [Related]
39. Manipulation of B-cell responses with histone deacetylase inhibitors.
Waibel M; Christiansen AJ; Hibbs ML; Shortt J; Jones SA; Simpson I; Light A; O'Donnell K; Morand EF; Tarlinton DM; Johnstone RW; Hawkins ED
Nat Commun; 2015 Apr; 6():6838. PubMed ID: 25913720
[TBL] [Abstract][Full Text] [Related]
40. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
West AC; Mattarollo SR; Shortt J; Cluse LA; Christiansen AJ; Smyth MJ; Johnstone RW
Cancer Res; 2013 Dec; 73(24):7265-76. PubMed ID: 24158093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
